Form 8-K - Current report:
SEC Accession No. 0001493152-24-042406
Filing Date
2024-10-24
Accepted
2024-10-24 17:18:07
Documents
23
Period of Report
2024-10-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 64314
2 ex4-1.htm EX-4.1 113242
3 ex4-2.htm EX-4.2 113174
4 ex4-3.htm EX-4.3 110680
5 ex5-1.htm EX-5.1 12033
6 ex10-1.htm EX-10.1 282845
7 ex10-2.htm EX-10.2 113441
8 ex99-1.htm EX-99.1 16576
9 ex5-1_001.jpg GRAPHIC 5377
10 ex99-1_001.jpg GRAPHIC 10238
  Complete submission text file 0001493152-24-042406.txt   1250130

Data Files

Seq Description Document Type Size
11 XBRL SCHEMA FILE cldi-20241023.xsd EX-101.SCH 3813
12 XBRL DEFINITION FILE cldi-20241023_def.xml EX-101.DEF 30090
13 XBRL LABEL FILE cldi-20241023_lab.xml EX-101.LAB 36817
14 XBRL PRESENTATION FILE cldi-20241023_pre.xml EX-101.PRE 27113
25 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5966
Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600
Calidi Biotherapeutics, Inc. (Filer) CIK: 0001855485 (see all company filings)

EIN.: 862967193 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40789 | Film No.: 241393481
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)